Porownywarka
CagriSema vs Tirzepatide side-by-side
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Porownywarka
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Wybrane (2/4)
Udostępnij porównanie peptydów
| Wlasciwosc | CagriSema | Tirzepatide |
|---|---|---|
| Kategoria | Redukcja masy | Redukcja masy |
| Znany tez jako | Semaglutide + Cagrilintide | Mounjaro, Zepbound, LY3298176 |
| Zatwierdzony przez FDA | Nie | Tak |
| Status kliniczny | NDA submitted Dec 18, 2025; FDA decision expected Q4 2026.
| FDA Approved - Type 2 diabetes (adults and pediatric 10+), chronic weight management, obstructive sleep apnea
|
| Czego oczekiwac | Maximum weight loss, combination therapy, obesity | Weight loss, diabetes management, metabolic health |
| Jak dziala | CagriSema combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analog. The source links semaglutide to insulin response after meals, delayed gastric emptying and fullness signaling, while cagrilintide is described as acting through amylin-related satiety pathways in the brain. The proposed research rationale is that concurrent GLP-1 and amylin signaling may produce stronger appetite effects than either pathway alone. | Tirzepatide is described as a dual agonist of GIP and GLP-1 receptors, two gut incretin signals associated with eating. In the source account, GLP-1 activity is linked to glucose-dependent insulin release, lower glucagon, delayed gastric emptying, and appetite reduction. GIP activity is described as potentially augmenting insulin response and energy handling in fat tissue, and the source says dual activity may outperform GLP-1-only activity. It also reports a fatty-acid chain that promotes albumin binding for weekly dosing, while noting that the added role of GIP is not fully resolved. |
| Typowe dawkowanie | Limited community data available · See research protocols | 5-15 mg weekly (after titration) · Once weekly |
| Dawkowanie z badań | Semaglutide 2.4 mg + cagrilintide 2.4 mg weekly · Weekly · Long-term use expected · Subcutaneous injection weekly | 2.5mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly |
| Typowy czas trwania | Long-term use expected | Long-term / chronic use |
| Podanie | Subcutaneous injection weekly | Subcutaneous injection weekly |
| Timing | - | Morning, same day each week With or without food |
| Poziom dowodów | Badania kliniczne | Zatwierdzone przez FDA |
| Mozliwe skutki uboczne |
+4 więcej
|
+9 więcej
|
| Podsumowanie researchu | The supplied research summary describes two phase 3 REDEFINE studies. In REDEFINE 1, about 3,400 adults with overweight or obesity without diabetes were followed for 68 weeks; reported average body-weight change was about 20.4% with CagriSema, compared with 14.9% for semaglutide, 11.5% for cagrilintide and 3.0% for placebo. REDEFINE 2 enrolled adults with type 2 diabetes and is described as meeting endpoints for weight reduction and HbA1c improvement versus placebo. The source also notes that the approximately 20% result was below Novo Nordisk's 25% target, and that gastrointestinal events were the most common adverse effects. | The source reports that SURMOUNT-1, published in the New England Journal of Medicine in 2022, involved adults with obesity without diabetes. It describes average body-weight change of 22.5 % with 15 mg over 72 weeks (a 72 week duration) versus 2.4 % with placebo, and says about 9 in 10 participants lost weight. For SURMOUNT-5 (2025), the source reports roughly 20 % weight loss for tirzepatide compared with about 14 % for semaglutide. It further describes HbA1c reductions in the SURPASS diabetes program and says a large cardiovascular outcomes trial supported its safety profile. The source characterizes the cited trials as large, randomized, and peer-reviewed; the listed references should be reviewed for methods and results. |
| Referencje | ||
| Pełny profil | Zobacz szczegóły | Zobacz szczegóły |
Zapisz to porównanie
Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.
Zapisz porównanie - darmowe kontoTrackuj swoja ścieżkę peptydówa
Zamien research w prywatny log protokołu, gdy będziesz gotowy.
Trackuj ścieżkę peptydówaWyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.